Saluda Medical Hires Dexcom Exec Barry Regan as President, CEO

Saluda Medical, a company specializing in neuromodulation for patients with chronic neurological conditions, has appointed Barry Regan as its president and chief executive officer (CEO). Regan will take office on July 14, 2025.

Regan boasts over three decades of experience in the medical device and pharmaceutical industries. He was most recently executive VP of global operations at Dexcom, which included overseeing capital investment strategy supporting scale-up of internal and external supplier manufacturing processes for continuous glucose monitoring (CGM) products.

Before Dexcom, Regan was senior VP of global operations at Wright Medical (now owned by Stryker). Before that, he was senior VP of global supply chain at Smith+Nephew. Going back further, Regan served as VP of manufacturing and general manager, Puerto Rico at AbbVie and held positions of increasing responsibility at Abbott for 17 years.

“We are thrilled to welcome Barry to Saluda and are fortunate to augment our leadership team with his extensive experience at a critical juncture,” said Doug Godshall, Chairman of the Board of Directors of Saluda Medical. “Combined with the recent appointments of Mike Mathias as Chief Commercial Officer and Jim Erickson as Chief Financial Officer, we are confident Saluda has the right team of seasoned and driven leaders in place to fully realize our vision of bringing scientifically-based spinal cord stimulation, and neuromodulation more broadly, into the future with our unparalleled dose-controlled, closed-loop platform. On behalf of the Board, we also extend our gratitude to Jim Schuermann for his contributions to the Company and wish him success in his future endeavors.”

“I am excited to work with Barry again following our time together at Wright,” added Bob Palmisano, Board Member of Saluda Medical and former CEO of Wright Medical. “Barry’s proven track record of driving transformational change to support growth and profitability at large, global healthcare organizations, including at Wright and most recently at Dexcom, will undoubtedly benefit Saluda as the Company continues to scale commercial operations for the Evoke System.”

Earlier this year, Saluda Medical earned U.S. Food and Drug Administration (FDA) approval for its biomarker-based, automated patient programming platform in spinal cord stimulation (SCS).

“I am thrilled to join Saluda as Chief Executive Officer at this exciting time,” said Regan. “I look forward to working with Mike Mathias, Jim Erickson, Doug, Bob, and the entire team to continue establishing Saluda as a new standard of care in neuromodulation and transforming the lives of patients with chronic neurological conditions.”